New cell and gene therapies create the promise of curing debilitating conditions that were previously thought to be incurable. These highly specialized and highly personalized therapies come with price tags in the millions of dollars for a single treatment. For example, new treatments could cure sickle cell disease for some of the 100,000 Americans who live with the disease. However, the two approved treatments are between $2 and 3 million per dose. And projecting demand is challenging: some patients may be reluctant to undergo new treatment.

How are public and private insurers thinking about paying for these therapies and how should they prepare for future breakthroughs? LDI’s expert panel will unpack the current landscape and options for increasing access to these treatments while creating sustainable payment strategies.